Effect of Unani drug Majoon chobchini and Leech therapy in patients of Psoriatic arthritis

Phase 2

• Conditions: Health Condition 1: M148- Arthropathies in other specified diseases classified elsewhere

• Registration Number: CTRI/2024/07/070050
• Lead Sponsor: Department of Ilaj Bit Tadbeer Faculty of Unani Medicine AMU Aligarh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Psoriatic lesion along with arthritis

2. Evidence of psoriasis (any of three)

a. Current: Psoriatic skin or scalp disease present, as judged by a

dermatologist or rheumatologist.

b. Personal history: May be obtained from the patient, family doctor,

dermatologist, or rheumatologist.

c. Family history: In a first or second degree relative, according to the patient report.

3. Seronegative RA Factor

4. Dactylitis

a. Current: swelling of an entire digit.

5. Plain X-rays of the affected Joints (Pencil in cup deformity, juxta articular new bone formation

and destruction).

6. USG of affected Joints (Tendinitis/ Enthemopathy).

(Diagnostic criteria - CASPAR Criteria 2006)

7. Patients Between the age group 30-60 years of either sex.

8. Patients on any concomitant therapy of Unani medicine for the problem of psoriasis.

9. Those patients agreed and signed the written consent proforma.

Exclusion Criteria

1. Doubtful cases of Psoriatic arthritis

2. Psoriatic arthritis with systemic illnesses like Diabetes mellitus, Chronic Liver

Disease & Chronic Kidney Diseases

3. Psoriatic arthritis with secondary infections

4. Immunocompromised patients

5. Below the age of 30 years and above the 60 years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in joint swelling and pain (Synovitis) <br/ ><br>Improvement in mobility of joints <br/ ><br>Improvement in USG finding particularly size joint space, bony erosion, inflammation of entheses (Enthesopathy).Timepoint: one year

Secondary Outcome Measures

Name	Time	Method
Improvement or check the destruction in X-Ray finding. <br/ ><br>VAS <br/ ><br>IL-17 and IL-23 <br/ ><br>Anti-LL-37 <br/ ><br>TNF-alphaTimepoint: one year